Expression of p53 isoforms in squamous cell carcinoma of the head and neck.

Recent data indicate that, similar to p63 and p73, several different p53 isoforms can be produced in humans through alternative initiation of translation, usage of an internal promoter and alternative splicing. These isoforms are reported to have varying functions and expressions. In squamous cell carcinoma of the head and neck (SCCHN), disruption of the p53 pathway is one of the most common genetic alterations. However, to our knowledge, no studies regarding the expression of different p53 isoforms in SCCHN have so far been performed. We screened for the expression of different p53 isoforms in SCCHN and clinically normal oral epithelia using nested RT-PCR. p53 mRNA was expressed in all tumours, all matched clinically normal tissue adjacent to the tumour and in buccal mucosa from healthy volunteers. Of the novel isoforms, p53beta was detected in the majority of samples analysed, and all of the recently described isoforms were also detected in at least some tumour and normal epithelium samples, with the exception of Deltap53 isoforms. We conclude that p53 variant mRNAs are expressed in both normal oral stratified epithelium and SCCHN. Improvements in methodologies and reagents to detect and quantify p53 isoform expression in clinical material will be required to correlate p53 status with clinical outcomes.

[1]  B. Sjöström,et al.  Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. , 2004, International journal of oncology.

[2]  A Estreicher,et al.  The human tumour suppressor gene p53 is alternatively spliced in normal cells. , 1996, Oncogene.

[3]  P. Hainaut,et al.  ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53 , 2002, Oncogene.

[4]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[5]  M. Gatei,et al.  Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53 , 2001, Oncogene.

[6]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[7]  B. Sjöström,et al.  Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers. , 2005, International journal of oncology.

[8]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[9]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[10]  P. Hall,et al.  The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[11]  D. Lane,et al.  p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress , 2006, Cell Death and Differentiation.

[12]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[13]  M. Kulesz-Martin,et al.  Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. , 1992, Nucleic acids research.

[14]  F. McKeon,et al.  An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. , 2000, Science.

[15]  V. Chow,et al.  Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. , 1993, Cancer letters.

[16]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[17]  Wolf,et al.  Immunologically distinct p53 molecules generated by alternative splicing , 1986, Molecular and cellular biology.

[18]  D. Lane,et al.  P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.

[19]  W. Deppert,et al.  A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.

[20]  J. Kovarik,et al.  Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. , 1995, Oncogene.

[21]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[22]  D. Lane,et al.  Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. , 1995, Journal of molecular biology.

[23]  V. Rotter,et al.  Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule , 1985, Molecular and cellular biology.

[24]  Yili Yin,et al.  p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products , 2002, Nature Cell Biology.

[25]  G. Matlashewski,et al.  Regulation of Human p53 Activity and Cell Localization by Alternative Splicing , 2004, Molecular and Cellular Biology.